MIT Researcher: Device and Drug Combos Carry Greater Risk, Reward

MIT researcher Michael Cima says by combining drug therapy with medical devices, manufacturers can see greater payoffs, according to a Mass Device report.

The drug-device combination becomes a complete therapy, and companies can see returns as early as the end of Phase II trials, Mr. Cima says. Although getting an FDA drug approval can be time-consuming and expensive, Mr. Cima says the payoff is greater. In some cases, medical device manufacturers can incorporate a drug that has already been approved in their device, he says.

Related Articles on Medical Devices:

FDA Extends Comment Period on 510(k) Document
World Sterilization Equipment and Supplies Market to Reach $3.31B by 2017
USC School of Pharmacy Establishes International Center for Regulatory Science

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers